These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14530491)

  • 1. Underestimation of absorbed dose to kidney.
    Postema EJ; Buijs WC; Boerman OC; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1707-8. PubMed ID: 14530491
    [No Abstract]   [Full Text] [Related]  

  • 2. Bias reduction in correlation of radiation-absorbed dose with response.
    Koral KF; Zasadny K; Wahl RL
    J Nucl Med; 2004 Jul; 45(7):1271; author reply 1271-2. PubMed ID: 15235076
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
    Goldenberg DM; Sharkey RM
    J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
    DeNardo G; Yuan A; Goldstein D; Richman C; O'Donnell R; Shen S; Hartmann Siantar C; DeNardo S
    Cancer Biother Radiopharm; 2003 Apr; 18(2):231-7. PubMed ID: 12804049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan.
    Cicone F; D'Arienzo M; Carpaneto A; Russo E; Coniglio A; Delaloye AB; Scopinaro F
    Cancer Biother Radiopharm; 2013 Mar; 28(2):98-107. PubMed ID: 23289952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
    DeNardo GL; DeNardo SJ; Kukis DL; O'Donnell RT; Shen S; Mirick GR; Meares CF
    J Nucl Med; 2001 Sep; 42(9):1324-33. PubMed ID: 11535720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
    O'Donnell RT; Leigh BR; Christensen SD; Goldstein DS; Kukis DL; Shen S; Yuan A; DeNardo DA; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
    Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
    Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
    [No Abstract]   [Full Text] [Related]  

  • 19. Radioimmunotherapy of Non-Hodgkin's lymphoma.
    Britton KE
    J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.